Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

20
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
20
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

18
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of...
18
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
Neural Regulation01:37

Neural Regulation

34.6K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
34.6K
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

27
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
27

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Effect of Benzodiazepines on Catatonia: A Systematic Review and Meta-Analysis.

Acta psychiatrica Scandinavica·2026
Same author

Associations between physical fitness and structural and functional MRI measures in secondary progressive multiple sclerosis: Cross-sectional findings from the exercise PRO-MS study.

Multiple sclerosis and related disorders·2025
Same author

The ins and outs of unpacking the black box: Understanding motivation using a multi-level approach.

The Behavioral and brain sciences·2025
Same author

Challenge or threat? A Q-methodological study into nursing students' perceptions on learning to collaborate under stress.

Nurse education today·2024
Same author

More rTMS pulses or more sessions? The impact on treatment outcome for treatment resistant depression.

Acta psychiatrica Scandinavica·2024
Same author

[The application of rTMS in OCD in the Netherlands and Belgium: consensus statement].

Tijdschrift voor psychiatrie·2024

Related Experiment Video

Updated: Apr 26, 2026

Technique for Intranasal Administration of α-Synuclein Aggregates
04:49

Technique for Intranasal Administration of α-Synuclein Aggregates

Published on: November 8, 2024

1.2K

Novelty processing and memory formation in Parkinson's disease.

J Schomaker1, H W Berendse2, E M J Foncke3

  • 1Department of Cognitive Psychology, VU University, Amsterdam, The Netherlands.

Neuropsychologia
|July 29, 2014
PubMed
Summary

Parkinson's disease patients show impaired learning of novel information and reduced brain responses associated with memory encoding. Dopamine replacement therapy did not improve these cognitive deficits in patients with Parkinson's disease.

Keywords:
DopamineLearningMemoryNovelty processingParkinson׳s diseaseVon Restorff effect

More Related Videos

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

16.7K
Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
10:03

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Published on: August 16, 2020

11.4K

Related Experiment Videos

Last Updated: Apr 26, 2026

Technique for Intranasal Administration of α-Synuclein Aggregates
04:49

Technique for Intranasal Administration of α-Synuclein Aggregates

Published on: November 8, 2024

1.2K
Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

16.7K
Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
10:03

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Published on: August 16, 2020

11.4K

Area of Science:

  • Neuroscience
  • Cognitive Psychology
  • Neurology

Background:

  • Parkinson's disease (PD) involves the degeneration of dopaminergic cells, leading to dopamine depletion.
  • Dopamine replacement therapy (DRT) is used to counteract dopamine depletion.
  • Dopamine influences novelty processing and memory, suggesting these functions are affected in PD and potentially by DRT.

Purpose of the Study:

  • To investigate word learning and novelty processing in Parkinson's disease patients.
  • To examine the role of dopamine replacement therapy (DRT) in these cognitive processes.
  • To analyze event-related potential components (P2 and P3) related to memory encoding in PD.

Main Methods:

  • A study involving 21 patients with PD and 21 healthy controls.
  • PD patients were tested both on and off dopamine replacement therapy (DRT) in a counterbalanced design.
  • Electroencephalogram (EEG) was recorded during a word learning task (Von Restorff task).

Main Results:

  • Healthy controls exhibited enhanced memory for novel stimuli (Von Restorff effect), while PD patients showed the opposite pattern.
  • Larger P3 event-related potentials for novel stimuli were observed in controls, but not in PD patients.
  • Both groups showed larger P2 and P3 components for recalled words; DRT did not influence these findings.

Conclusions:

  • Learning of novel information is compromised in Parkinson's disease patients.
  • Reduced P2 and P3 event-related components, indicative of memory encoding, were observed in PD patients.
  • These cognitive and neural deficits in PD are not resolved by dopaminergic medication.